Emerging treatments

Nelotanserin

The Food and Drug Administration (FDA) has granted fast track designation to nelotanserin, a novel 5-HT2A inverse agonist, for the treatment of visual hallucinations disorder in DLB. One small, double-blind randomized study demonstrated no difference in behaviors associated with rapid eye movement sleep behavior disorder between patients (with either DLB or Parkinson disease dementia) taking nelotanserin compared with placebo.[72]

Intepirdine

A selective 5-HT6 receptor antagonist that increases extracellular acetylcholine and glutamate. One randomized, placebo-controlled, phase 2b clinical trial reported that intepirdine did not lead to improvements compared with placebo in patients with DLB.[73]

Mevidalen

A selective positive allosteric modulator of the dopamine D1 receptor subtype. In one randomized, placebo-controlled phase 2 trial, mevidalen was associated with improvement in the motor symptoms of DLB while improving or not worsening nonmotor symptoms - including cognition - that are associated with classic dopaminergic therapy.[74]

Neflamapimod

An oral p38 alpha kinase inhibitor that has shown promising results in one phase 2 clinical trial investigating effects on cognitive function in patients with DLB.[75]

Dextromethorphan quinidine

This drug combination is FDA-approved for pseudobulbar affect and is being investigated for agitation in dementia.[76]

Cannabinoids

Under investigation for dementia-related agitation and aggression.[77][78]

Use of this content is subject to our disclaimer